<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05038943</url>
  </required_header>
  <id_info>
    <org_study_id>0478-21-FB</org_study_id>
    <nct_id>NCT05038943</nct_id>
  </id_info>
  <brief_title>Evaluation of Safety and Effectiveness of The SherpaPak in Donation After Circulatory Death Heart Transplantation</brief_title>
  <official_title>Evaluation of Safety and Effectiveness of The Paragonix™ SherpaPak Cardiac Transport System in Donation After Circulatory Death Heart Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nebraska</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Nebraska</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, pilot trial to evaluate the safety and effectiveness of The Paragonix&#xD;
      SherpaPak™ Cardiac Transport System (&quot;SherpaPak CTS&quot;) in transportation of cardiac allografts&#xD;
      recovered from donors after circulatory death with thoracoabdominal normothermic regional&#xD;
      perfusion (TA-NRP). SherpaPak™ CTS is an ultraportable hypothermic preservation and transport&#xD;
      system that has been approved by United States Food &amp; Drug Administration (FDA) for clinical&#xD;
      use in heart transplantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will accept donors between the ages of 18 and 49 without any known history&#xD;
      of coronary artery disease, insulin dependent diabetes, or long-term smoking (&gt;20 pack/years)&#xD;
      and normal baseline cardiac function (EF&gt;50) assessed with transthoracic echocardiogram.&#xD;
      Donors will be selected and matched to the recipients based on standard criteria (blood&#xD;
      group, cross-match, size match, and clinical stability). The current procedure of donation&#xD;
      after circulatory death (DCD) and procurement follows a well-established course. After&#xD;
      consent is obtained, the organs are allocated through United Network for Organ Sharing&#xD;
      (UNOS). All organs will be recovered with protocolized UNMC DCD TA-NRP technique that&#xD;
      involves reestablishment of blood flow in-situ after donor's circulatory arrest using&#xD;
      portable venoarterial extracorporeal membrane oxygenation (VA-ECMO). Organs will be&#xD;
      transported from a donor site to recipient center with the SherpaPak™ CTS. All organs will be&#xD;
      transplanted at Nebraska Medicine. Recipients (&quot;subjects&quot;) will be followed from transplant&#xD;
      through one-year post-transplantation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Cardiac allografts recovered from donors after circulatory death with thoracoabdominal normothermic regional perfusion will be transported with Paragonix SherpaPak Cardiac Transport System to the recipient center</intervention_model_description>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Graft Dysfunction (PGD)</measure>
    <time_frame>72 hours</time_frame>
    <description>PGD will be classified according to International Society for Heart and Lung Transplantation (ISHLT) classification into: PGD-LV Grade 1 (LVEF ≤ 40% by echocardiography, or Hemodynamics with RAP &gt; 15 mm Hg, PCWP &gt; 20 mm Hg, CI &lt; 2.0 L/min/m2 (lasting more than 1 hour) requiring low-dose inotropes); PGD-LV Grade 2 (I. One criteria from the following: Left ventricular ejection fraction ≤ 40%, or Hemodynamic compromise with RAP &gt; 15 mm Hg, PCWP &gt; 20 mm Hg, CI &lt; 2.0 L/min/m2, hypotension with MAP &lt; 70 mm Hg (lasting more than 1 hour) II. One criteria from the following: High-dose inotropes-Inotrope score &gt;10, or Newly placed IABP (regardless of inotropes)); PGD-LV Grade 3 ( Dependence on left or biventricular mechanical support including ECMO, LVAD, BiVAD, or percutaneous LVAD. Excludes requirement for IABP; PGD-RV (I. Hemodynamics with RAP &gt; 15 mm Hg, PCWP &lt; 15 mm Hg, CI &lt; 2.0 L/min/m2, II. TPG &lt; 15 mm Hg and/or pulmonary artery systolic pressure &lt; 50 mm Hg, III. Need for RVAD)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Need for cardioversion or pacing to restart transplanted heart</measure>
    <time_frame>72 hours</time_frame>
    <description>Need for cardioversion or pacing to restart transplanted heart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasoactive-inotropic score (VIS)</measure>
    <time_frame>24, 48, and 72 hours</time_frame>
    <description>The vasoactive-inotropic score (VIS) will be calculated as a weighted sum of all administered inotropes and vasoconstrictors, reflecting pharmacological support of the cardio-vascular system. Formula for VIS calculation: dopamine dose (µg/kg/min) + dobutamine dose (µg/kg/min) + 100 x epinephrine dose (µg/kg/min) + 100 x norepinephrine dose (µg/kg/min).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of vasoactive-inotropic support in days</measure>
    <time_frame>1 year</time_frame>
    <description>Duration of vasoactive-inotropic support in days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive Care Unit &amp; Hospital length of stay in days</measure>
    <time_frame>1 year</time_frame>
    <description>Intensive Care Unit &amp; Hospital length of stay in days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival at discharge</measure>
    <time_frame>1 year</time_frame>
    <description>Survival at discharge 30-day, 90-day, 1-year</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Heart Transplant Failure</condition>
  <condition>Determination of Death</condition>
  <condition>Outcomes Research</condition>
  <condition>Extracorporeal Membrane Oxygenation</condition>
  <arm_group>
    <arm_group_label>SherpaPak</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cardiac allografts recovered from donors after circulatory determined death using thoracoabdominal normothermic regional perfusion will be transported to the recipient center in Paragonix SherpaPak Cardiac Transport System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Paragonix SherpaPak Cardiac Transport System</intervention_name>
    <description>Transportation of cardiac allografts in a device maintaining constant optimal temperature to minimize freezing tissue injury</description>
    <arm_group_label>SherpaPak</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Recipient is ≥ 19 years old&#xD;
&#xD;
          2. Recipient, or their designated healthcare proxy, is able and willing to sign informed&#xD;
             consent&#xD;
&#xD;
          3. Recipient meets standard listing criteria for heart transplantation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Recipient is &lt; 19 years old&#xD;
&#xD;
          2. Recipient, or their designated healthcare proxy, is unable to sign informed consent&#xD;
&#xD;
          3. Recipient has any condition that, in the opinion of the Investigator, would make study&#xD;
             participation unsafe or would interfere with the objectives of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marian Urban, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistant Professor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rachel E Halstead (Gross), RN, BSN</last_name>
    <phone>402-559-3665</phone>
    <email>rachel.gross@unmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Barbara Hoover-Schultz, MS, MPA</last_name>
    <phone>402-559-0869</phone>
    <email>b.hooverschultz@unmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel E Gross, RN, BSN</last_name>
      <phone>402-559-3665</phone>
      <email>rachel.gross@unmc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Radakovic D, Karimli S, Penov K, Schade I, Hamouda K, Bening C, Leyh RG, Aleksic I. First clinical experience with the novel cold storage SherpaPak™ system for donor heart transportation. J Thorac Dis. 2020 Dec;12(12):7227-7235. doi: 10.21037/jtd-20-1827.</citation>
    <PMID>33447411</PMID>
  </results_reference>
  <results_reference>
    <citation>Toldo S, Quader M, Salloum FN, Mezzaroma E, Abbate A. Targeting the Innate Immune Response to Improve Cardiac Graft Recovery after Heart Transplantation: Implications for the Donation after Cardiac Death. Int J Mol Sci. 2016 Jun 17;17(6). pii: E958. doi: 10.3390/ijms17060958. Review.</citation>
    <PMID>27322252</PMID>
  </results_reference>
  <results_reference>
    <citation>Kobashigawa J, Zuckermann A, Macdonald P, Leprince P, Esmailian F, Luu M, Mancini D, Patel J, Razi R, Reichenspurner H, Russell S, Segovia J, Smedira N, Stehlik J, Wagner F; Consensus Conference participants. Report from a consensus conference on primary graft dysfunction after cardiac transplantation. J Heart Lung Transplant. 2014 Apr;33(4):327-40. doi: 10.1016/j.healun.2014.02.027. Epub 2014 Mar 5.</citation>
    <PMID>24661451</PMID>
  </results_reference>
  <results_reference>
    <citation>Yamazaki Y, Oba K, Matsui Y, Morimoto Y. Vasoactive-inotropic score as a predictor of morbidity and mortality in adults after cardiac surgery with cardiopulmonary bypass. J Anesth. 2018 Apr;32(2):167-173. doi: 10.1007/s00540-018-2447-2. Epub 2018 Jan 13.</citation>
    <PMID>29332153</PMID>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 31, 2021</study_first_submitted>
  <study_first_submitted_qc>September 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Nebraska</investigator_affiliation>
    <investigator_full_name>Marian Urban</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Transplantation, heart</keyword>
  <keyword>Normothermic Regional Perfusion</keyword>
  <keyword>Organ transport</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Death</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

